Protalix BioTherapeutics, Inc. reports $3.1 million Q1 loss

Protalix BioTherapeutics, Inc. [PLX] has reported fiscal Q1 loss of $3.10 million.

On a per-share basis, the DE based company said its diluted earnings are $0.05.

The Biological Products, Except Diagnostic Substances firm posted revenue of $5.10 million in this period.